Transaction · 0001352620-26-000006

Hasnain Faheem

Hasnain Faheem, PRES, CEO, reported a transaction classified as grant at Gossamer Bio, Inc. involving 166.000000 shares for an estimated $165999.83. Reported holdings after the transaction were 166.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code APRES, CEO
GOSSGossamer Bio, Inc.
Trade date
Aug 24, 2026
Filing date
Aug 26, 2026
View on SEC Insider profile
Estimated value$165kShares × reported price
Shares traded166$1,000.00 per share
Holdings after166Indirect · By Family Trust
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

GOSS price since this filing

Daily closing prices, with the filing date and available return windows
GOSS · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -23.5%1w ago -17.6%1d ago -11.8%
Returns since7d +0.0%30d +6335.3%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001352620-26-000006
Pre-Funded Warrant (Right to Buy)
Transaction date
Aug 24, 2026
Filed Aug 26, 2026, 10:08 PM · 2d delay
Shares
166 sh
$1,000.00 per share
Estimated value
$165k
Computed from shares × price
Holdings after
166 sh
Indirect · By Family Trust

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Large Holdings Increase
Filing-only score

-12 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President & CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Each share of Series A-1 non-voting convertible preferred stock is convertible automatically upon receipt of stockholder approval under applicable Nasdaq rules and regulations in connection with the I…

  2. F2

    The Pre-Funded Warrant has no expiration date and is exercisable immediately. Prior to the Issuer obtaining Stockholder Approval, the Pre-Funded Warrants are only exercisable for shares of Series A-1…

  3. F3

    50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the…

Original filing · 0001352620-26-000006
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

GOSS